Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification.

ST, Kim; HL, Jang; SJ, Lee; J, Lee; YL, Choi; KM, Kim; J, Cho; SH, Park; YS, Park; HY, Lim; M, Yashiro; WK, Kang; JO, Park

doi:10.1158/1535-7163.mct-14-0255

Public

Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification.

Shared by NobleBlocks on Sep 23, 2014 • 12:00 AM UTC

Authors:

Kim ST

Jang HL

Lee SJ

Abstract

Pazopanib is an orally bioavailable, ATP-competitive, multitargeted tyrosine kinase inhibitor mainly targeting VEGFR2 and PDGFR tyrosine kinases, but the biologic sequences of pazopanib activities beyond antiangiogenesis are poorly defined. We used a panel of 38 gastric cancer cell lines to test the...

Discussions